BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MedCap Corp. (MPCPF.PK) Announces Test Kits Receive Certification


10/19/2005 5:13:05 PM

TORONTO, March 21 /PRNewswire-FirstCall/ -- MedCap Corp (Pinksheets: MPCPF) is pleased to announce that the AccuScan Drugs of Abuse have received Health Canada manufacturers certificate to cover the export of medical devices. This certification of the test kits will be very helpful in its marketing program, particularly in China.

Preliminary test results in China have been excellent. The certifications combined with the test results should result in significant orders within the next 60 days. The certification verifies that the kits are produced using GMP standards.

The Company is continuing to negotiate with distributors for the AccuScan in different parts of the world based on market studies which show the areas of greatest potential.

MedCap trades in the United States on the Pinksheets under the symbol "MPCPF". For further information, please contact Cazgeld Capital Corporation at (416) 363 0070 or at http://www.medccorp.com/ .

NOTE: This release may contain forward-looking statements that involve uncertainties and risks. Actual results may differ materially from any results predicted. MedCap undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events of circumstances after the date hereof.

MedCap Corp

CONTACT: Cazgeld Capital Corporation, +1-416-363-0070



Read at BioSpace.com

   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES